Table 2.
Interaction between nanoparticles and neutrophils
| NP carriers | Functional molecules | Function | Diseases | References |
|---|---|---|---|---|
| Poly(lactide-coglycolide) (PLG) NPs | – | Modulating neutrophil migration | Spinal cord injury | [80] |
| Polystyrene (PS) NPs | Fluorescent carboxylate | Modulating neutrophil migration | Acute lung injury | [88] |
| PLG NPs | – | Modulating neutrophil migration | Autoimmune encephalomyelitis | [89] |
| Albumin NPs | DOX | Depleting activated neutrophils | Acute lung inflammation and ischemic stroke | [90] |
| Polydopamine-poly (ethylene glycol) NPs | DNase-1 | Suppressing neutrophil proliferation and activity | Sepsis | [93] |
| Albumin NPs | Piceatannol | Neutrophil-based drug delivery | Acute lung injury | [94] |
| Albumin NPs | TPCA-1 | Neutrophil-based drug delivery | Acute lung inflammation; bacterial infection | [96] |
| DGL NPs modified with PGP | Catalase | Neutrophil-based drug delivery | Cerebral ischemia | [97] |
| PLGA NPs | Neutrophil membrane coating | Neutralizing proinflammatory cytokines | Rheumatoid arthritis | [98] |
| Coenzyme Q NPs | Neutrophil membrane coating | Suppressing oxidative damages | Ischemia–reperfusion injury | [99] |
| Neutrophil membrane-derived nanovesicles | TPCA-1 | Nanovesicle-based drug delivery | Acute lung inflammation | [100] |
| Neutrophil membrane-derived nanovesicles | Piceatannol | Nanovesicle-based drug delivery | Sepsis | [101] |